Difference between revisions of "Timeline of malaria vaccine"

From Timelines
Jump to: navigation, search
 
(69 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
This is a '''timeline of [[wikipedia:malaria vaccine|malaria vaccine]]''', attempting to describe its development.
+
This is a '''timeline of [[wikipedia:malaria vaccine|malaria vaccine]]''', attempting to describe its development. Efforts to develop effective vaccines span for more than six decades.<ref name="Vaccines against malaria"/>
 +
 
 +
== Big picture ==
  
−
==Big picture==
 
 
{| class="sortable wikitable"
 
{| class="sortable wikitable"
−
! Year/period !! Key developments
+
! Year/period !!Key development 
 +
|-
 +
| 1940s-1984 || Malaria immunization studies are conducted with aims at developing vaccines.<ref name="Vaccines against malaria"/>
 +
|-
 +
| 1984 onward || [[wikipedia:RTS,S|RTS,S]], the first malaria vaccine candidate is developed.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/>
 +
|-
 +
| 1995 onward || [[wikipedia:RTS,S|RTS,S]] malaria vaccine candidate trials start to be conducted, mostly in Africa.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/>
 
|-
 
|-
 +
| Present time || No effective malaria vaccine exists as of yet.<ref>{{cite web|title=Current Obstacles to Development THE SCIENCE|url=https://www.nap.edu/read/9027/chapter/6|website=nap.edu|accessdate=24 April 2017}}</ref>
 
|-
 
|-
 
|}
 
|}
  
−
==Full timeline==
+
== Timeline ==
 
{| class="sortable wikitable"
 
{| class="sortable wikitable"
 
! Year/period !! Type of event !! Event !!Location
 
! Year/period !! Type of event !! Event !!Location
 
|-
 
|-
−
| 1984 || || "GSK/WRAIR initiate collaboration"<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
+
| 1942 || Immunology development || Studies of inactivated sporozoite immunization show apparently beneficial effect of combining induction of cellular and humoral [[wikipedia:immune response|immune responses]] against malaria of domestic [[wikipedia:fowl|fowl]].<ref name="Vaccines against malaria"/> ||
 
|-
 
|-
−
| 1987 || || "RTS,S is first created by combining the malaria CS protein and hepatitis B surface antigen"<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/>
+
| 1950s || Immunology development || Research finds that immunization of [[wikipedia:chicken|chickens]] with a mix of asexual and sexual stages of ''[[wikipedia:plasmodium gallinaceum|plasmodium gallinaceum]]'' blocks parasite infectivity.<ref name="Transmission blocking malaria vaccines: Assays and candidates in clinical development">{{cite journal|title=Transmission blocking malaria vaccines: Assays and candidates in clinical development|doi=10.1016/j.vaccine.2015.08.073|url=http://www.sciencedirect.com/science/article/pii/S0264410X1501213X|accessdate=25 April 2017}}</ref> ||
−
"The RTS,S malaria vaccine candidate is the most advanced in development globally. It was created in 1987 by scientists working at GlaxoSmithKline’s (GSK) laboratories."<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
 
 
|-
 
|-
−
| 1995 || || "First RTS,S clinical tests in humans begins in adults in US"<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/>
+
| 1967 || Immunology development || Research on [[wikipedia:avian malaria|avian malaria]] shows that killed sporozoites as well as sporozoites inactivated with [[wikipedia:ultraviolet light|ultraviolet light]] can produce a partial [[wikipedia:immunity|immunity]] after injection into [[wikipedia:birds|birds]].<ref>{{cite web|title=Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei|url=http://www.nature.com/nature/journal/v216/n5111/abs/216160a0.html|website=nature.com|accessdate=18 April 2017}}</ref><ref name="Malaria Vaccine Design: Immunological Considerations">{{cite web|title=Malaria Vaccine Design: Immunological Considerations|url=http://www.sciencedirect.com/science/article/pii/S1074761310003651|website=sciencedirect.com|accessdate=18 April 2017}}</ref> During the 1960s, the path to malaria vaccine development consolidates with immunization studies of [[wikipedia:mouse|mice]] with irradiated sporozoites, and posterior analyses of the mechanisms of immunity in this model.<ref name="Vaccines against malaria">{{cite web|title=Vaccines against malaria|url=http://rstb.royalsocietypublishing.org/content/366/1579/2806|website=royalsocietypublishing.org|accessdate=18 April 2017}}</ref> ||
 
|-
 
|-
−
| 1997 || || "RTS,S" "Key proof-of-concept (PoC) study shows 6 of 7 volunteers in challenge trial are 100% protected."<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
+
| 1970 || Immunology development || Research reveals immune cross protection against malaria in [[wikipedia:rodent|rodent systems]].<ref name="Antimalarial Drugs I: Biological Background, Experimental Methods, and Drug Resistance">{{cite book|last1=Peters|first1=Wallace|title=Antimalarial Drugs I: Biological Background, Experimental Methods, and Drug Resistance|url=https://books.google.com.ar/books?id=K2vwCAAAQBAJ&pg=PA104&lpg=PA104&dq=%22cox%22+%221970%22+%22malaria%22&source=bl&ots=_1f01C2m2o&sig=NbV7k4z5Ur9f-eqDrQiU49UKZbw&hl=en&sa=X&ved=0ahUKEwi9h6bruq_TAhWLfpAKHTzeAawQ6AEIOjAF#v=onepage&q=%22cox%22%20%221970%22%20%22malaria%22&f=false|accessdate=19 April 2017}}</ref> ||
 
|-
 
|-
−
| 1998 || Trial || "First RTS,S trials in Africa begin in Gambia".<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
+
| 1983 || Publication || The first publications for cloning malaria [[wikipedia:antigen|antigen]]s appear.<ref name="Malaria Vaccine Design: Immunological Considerations"/> ||
 
|-
 
|-
−
| 1999 || || "The PATH Malaria Vaccine Initiative (PATH/MVI) is a programme established at PATH
+
| 1984 || Program launch || The [[wikipedia:Walter Reed Army Institute of Research|Walter Reed Army Institute of Research]] (WRAIR) and British pharmaceutical company [[wikipedia:GlaxoSmithKline|GlaxoSmithKline]] (GSK) initiate collaboration to produce a malaria vaccine using GSK’s recombinant [[wikipedia:escherichia coli|escherichia coli]] expression systems.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/><ref>{{cite journal|last1=Ripley Ballou|first1=W.|last2=Cahill|first2=Conor P.|title=Two Decades of Commitment to Malaria Vaccine Development: Glaxosmithkline Biologicals|url=https://www.ncbi.nlm.nih.gov/books/NBK1706/|accessdate=19 April 2017}}</ref> ||
−
in 1999. PATH/MVI’s mission is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries."<ref name="Mosquirix™"/> ||
 
 
|-
 
|-
−
| 2001 || || "GSK/MVI partnership initiated"  "n January 2001, GSK and PATH’s Malaria Vaccine Initiative (PATH/MVI), with grant monies from the Bill & Melinda Gates Foundation to PATH, entered into a public-private partnership to develop RTS,S for infants and young children living in malaria-endemic regions in sub-Saharan Africa."<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/>||
+
| 1985 || Immunology development || Researchers find that immunization with processed fragments of called Merozoite surface protein-1 MSP-1 (one of the most studied of all malaria [[wikipedia:protein|proteins]]) induce protective immune responses.<ref name="Malaria vaccines 1985–2005: a full circle?">{{cite web|title=Malaria vaccines 1985–2005: a full circle?|url=http://www.columbia.edu/itc/hs/medical/pathophys/id/2005/Larussa-TargettMalariaVacs.pdf|website=columbia.edu|accessdate=22 April 2017}}</ref> ||
 
|-
 
|-
−
| 2004 || || "Koy PoC study in children in the Mozambique"<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
+
| 1986-1987 || Immunology development || Team lead by Colombian Professor [[wikipedia:Manuel Elkin Patarroyo|Manuel Elkin Patarroyo]] inoculates hundreds of [[wikipedia:aotus monkey|aotus monkeys]] with experimental synthetic proteins designed to imitate bite of malaria proteins. By 1987 Patarroyo reports in [[wikipedia:Nature Magazine|Nature Magazine]] that three particular synthetic proteins protect a significant proportion of monkeys. However, a carrier molecule used to present the peptides to the monkeys’ immune systems appears to damage the animals’ livers.<ref name="One Colombian's Quest For A Malaria Vaccine">{{cite web|title=One Colombian's Quest For A Malaria Vaccine|url=http://www.the-scientist.com/?articles.view/articleNo/10052/title/One-Colombian-s-Quest-For-A-Malaria-Vaccine/|website=the-scientist.com|accessdate=22 April 2017}}</ref> || [[wikipedia:Colombia|Colombia]]
 
|-
 
|-
−
| 2006 || || The Malaria Vaccine Technology Roadmap launches.<ref name="Immunization, Vaccines and Biologicals">{{cite web|title=Immunization, Vaccines and Biologicals|url=http://www.who.int/immunization/topics/en/|website=who.int|accessdate=17 April 2017}}</ref> ||  
+
| 1987 || Vaccine development || Researchers working at [[wikipedia:GlaxoSmithKline|GlaxoSmithKline]]’s (GSK) laboratories, develop malaria vaccine candidate [[wikipedia:RTS,S|RTS,S]] (Mosquirix TM).<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> It is the first vaccine created by combining the malaria CS protein and [[wikipedia:hepatitis B|hepatitis B]] surface antigen.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || [[wikipedia:United Kingdom|United Kingdom]]
 
|-
 
|-
−
| 2007 || || "Phase II results in African children and infants published  in the LANCET and NEJM"<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
+
| 1993 || Vaccine development || Study on multi-stage, multi-component malaria vaccine cocktail featuring pre-erythrocytic, blood, and sexual stage antigens gives favourable results, however, further clinical development of this approach would not be reported.<ref>{{cite web|title=Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate—Tackling the Cocktail Challenge|url=http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0131456|website=plos.org|accessdate=25 April 2017|doi=10.1371/journal.pone.0131456}}</ref> ||
 
|-
 
|-
−
| 2009 || Trial || "RTS,S" "Phase III study start"<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> "GlaxoSmithKline Biologicals' (GSKBio) RTS,S" "A Phase III trial of the world’s most clinically advanced malaria vaccine candidate was launched in Kisumu, Kenya, in July 2009, under the auspices of the Kenya Medical Research Institute (KEMRI)/CDC Research and Public Health Collaboration."<ref>{{cite web|title=Malaria Vaccine|url=https://www.cdc.gov/malaria/features/vaccines.html|website=cdc.gov|accessdate=17 April 2017}}</ref> "The RTS,S Phase III efficacy and safety trial—the largest malaria vaccine trial in Africa to date—beganin May 2009 and ended in early 2014. The trial involved 15,459 infants and young children at 11 sites in seven African countries(Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania)."<ref name="Mosquirix™">{{cite web|title=Fact sheet: R TS,S malaria vaccine candidate (Mosquirix™)|url=http://www.malariavaccine.org/sites/www.malariavaccine.org/files/content/page/files/RTSS%20vaccine%20candidate%20Factsheet_FINAL.pdf|website=malariavaccine.org|accessdate=17 April 2017}}</ref><ref name="Advances and challenges in malaria vaccine development">{{cite journal|title=Advances and challenges in malaria vaccine development|doi=10.1172/JCI44423|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994342/|accessdate=17 April 2017|pmc=2994342}}</ref>||
+
| 1995 || Vaccine development (trial) || First [[wikipedia:RTS,S|RTS,S]] vaccine clinical tests in humans are conducted in adults in the United States.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || [[wikipedia:United States|United States]]
 
|-
 
|-
−
| 2011 || Trial || "The RTS,S vaccine was tested in Phase III trials in 11 different African countries. These trials have had some successes. The earliest results, released in October 2011, showed that in children aged 5-17 months, vaccination with RTS,S reduced the risk of clinical malaria and severe malaria by 56% and 47%, respectively.[17]  However, in results released in November 2012, the vaccine was less effective in infants aged 6-12 weeks at first vaccination."<ref name="Malaria and Malaria Vaccine Candidates">{{cite web|title=Malaria and Malaria Vaccine Candidates|url=https://www.historyofvaccines.org/content/articles/malaria-and-malaria-vaccine-candidates|website=historyofvaccines.org|accessdate=17 April 2017}}</ref>
+
| 1997 || Vaccine development (trial) || [[wikipedia:RTS,S|RTS,S]] vaccine Key proof-of-concept (PoC) study shows 100% protection in 6 of 7 volunteers in challenge trial.<ref name="Fact  s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
 
|-
 
|-
−
| 2013 || || "Malaria Vaccine Technology Roadmap (launched in 2006) has been updated in November 2013. The updated Roadmap represents a blueprint for second generation malaria vaccine development, including a new Vision, two new Strategic Goals and 13 priority activities"<ref name="Immunization, Vaccines and Biologicals"/>||
+
| 1998 || Vaccine development (trial) || First [[wikipedia:RTS,S|RTS,S]] vaccine trials in [[wikipedia:Africa|Africa]] are conducted in Gambia.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> || [[wikipedia:Gambia|Gambia]]
 
|-
 
|-
−
| 2015 (July) || || "The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced on July 24, 2015,that it has adopted a positive scientific opinion, under Article 58, for GSK’s malaria candidate vaccine Mosquirix TM, also known as RTS,S, in children aged 6 weeks to 17 months."<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )">{{cite web|title=Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )|url=http://www.malariavaccine.org/files/MVI-GSK-RTSSfactsheetFINAL-web.pdf|accessdate=17 April 2017}}</ref><ref name="Questions and answers on RTS,S/ASO1 malaria vaccine"/> ||
+
| 1999 || Program launch || The [[wikipedia:PATH (global health organization)#Malaria|PATH Malaria Vaccine Initiative (MVI)]] is established, with aims at accelerating the development of malaria vaccines and catalyzing timely access in endemic countries. <ref name="Mosquirix™"/><ref>{{cite web|title=Malaria Vaccine Initiative|url=http://www.inyvax.eu/mvi|website=inyvax.eu|accessdate=18 April 2017}}</ref> The program launches with a $50 million grant from the [[wikipedia:Bill & Melinda Gates Foundation|Bill & Melinda Gates Foundation]].<ref>{{cite web|title=PATH Malaria Vaccine Initiative (MVI): Accelerating Malaria Vaccine Development|url=https://www.devex.com/impact/partnerships/path-malaria-vaccine-initiative-mvi-249|website=devex.com|accessdate=25 April 2017}}</ref> ||
 
|-
 
|-
−
| 2016 || || "The January 2016 WHO position paper that followed the CHMP opinion endorses the recommendations made by the WHO Strategic Advisory Group of Experts (SAGE)on Immunization and Malaria Policy Advisory Committee (MPAC) in October 2015. According to the position paper, “WHO recommends that the pilot implementations use the 4-dose schedule of the RTS,S/AS01 vaccine in 3–5 distinct epide
+
| 2001 || Organization || The GSK/MVI partnership ([[wikipedia:GlaxoSmithKline|GlaxoSmithKline]] and [[wikipedia:PATH (global health organization)#Malaria|PATH Malaria Vaccine Initiative (MVI)]]) initiates, with grants from the [[wikipedia:Bill & Melinda Gates Foundation|Bill & Melinda Gates Foundation]] to PATH, with aims at developing [[wikipedia:RTS,S|RTS,S]] vaccine for infants and young children living in malaria-endemic regions in [[wikipedia:Sub-Saharan Africa|Sub-Saharan Africa]]."<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/>||
−
miological settings in sub-Saharan Africa, at subnational level, covering moderate-to-high transmission settings,”with three doses administered to children between 5 and 9 months of age, followed by a fourth dose 15–18 months later."<ref name="Mosquirix™"/>
+
|-
 +
| 2003 || Vaccine development (trial) || RTS,S/AS02A malaria vaccine candidate phase IIb clinical trial is conducted in children from 1 to 4 years of age in Mozambique. The vaccine shows to be safe, immunogenic and efficacious, reducing ''[[wikipedia:plasmodium falciparum|plasmodium falciparum]]'' clinical malaria cases by 30% and episodes of severe disease by up to 58%. In addition, protection would appear to last for a 18 month follow‐up period.<ref>{{cite journal|title=Towards an effective malaria vaccine|doi=10.1136/adc.2005.092551|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2066178/|accessdate=25 April 2017|pmc=2066178}}</ref> || [[wikipedia:Mozambique|Mozambique]]
 +
|-
 +
| 2006 || Program launch || The [[wikipedia:Malaria Vaccine Technology Roadmap|Malaria Vaccine Technology Roadmap]] launches.<ref name="Immunization, Vaccines and Biologicals">{{cite web|title=Immunization, Vaccines and Biologicals|url=http://www.who.int/immunization/topics/en/|website=who.int|accessdate=17 April 2017}}</ref><ref>{{cite journal|title=Malaria vaccine technology roadmap|doi=10.1016/S0140-6736(13)62238-2|url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62238-2/fulltext|accessdate=18 April 2017}}</ref> ||
 +
|-
 +
| 2007 || Publication || Phase II results in African children and infants are published in [[wikipedia:The Lancet|The Lancet]] and [[wikipedia:The New England Journal of Medicine|The New England Journal of Medicine]].<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/> ||
 +
|-
 +
| 2009-2014 || Vaccine development (trial) || [[wikipedia:RTS,S|RTS,S]] vaccine phase III study is launched in [[wikipedia:Kisumu|Kisumu]], Kenya, in July, under the auspices of the [[wikipedia:Kenya Medical Research Institute|Kenya Medical Research Institute]] (KEMRI)/CDC Research and Public Health Collaboration.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )"/><ref>{{cite web|title=Malaria Vaccine|url=https://www.cdc.gov/malaria/features/vaccines.html|website=cdc.gov|accessdate=17 April 2017}}</ref> The trial would end in  2014, involving 15,459 infants and young children at 11 sites in seven African countries, being the largest malaria vaccine trial in Africa to date.<ref name="Mosquirix™">{{cite web|title=Fact sheet: R TS,S malaria vaccine candidate (Mosquirix™)|url=http://www.malariavaccine.org/sites/www.malariavaccine.org/files/content/page/files/RTSS%20vaccine%20candidate%20Factsheet_FINAL.pdf|website=malariavaccine.org|accessdate=17 April 2017}}</ref><ref name="Advances and challenges in malaria vaccine development">{{cite journal|title=Advances and challenges in malaria vaccine development|doi=10.1172/JCI44423|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994342/|accessdate=17 April 2017|pmc=2994342}}</ref> || [[wikipedia:Burkina Faso|Burkina Faso]], [[wikipedia:Gabon|Gabon]], [[wikipedia:Ghana|Ghana]], [[wikipedia:Kenya|Kenya]], [[wikipedia:Malawi|Malawi]], [[wikipedia:Mozambique|Mozambique]], and [[wikipedia:Tanzania|Tanzania]]
 +
|-
 +
| 2011 || Vaccine development (trial) || [[wikipedia:RTS,S|RTS,S]] vaccine Phase III trials results, released in October, show that in children aged 5-17 months, vaccination with RTS,S reduce the risk of clinical malaria and severe malaria by 56% and 47%, respectively. However, further results released show the vaccine less effective in infants aged 6-12 weeks at first vaccination.<ref name="Malaria and Malaria Vaccine Candidates">{{cite web|title=Malaria and Malaria Vaccine Candidates|url=https://www.historyofvaccines.org/content/articles/malaria-and-malaria-vaccine-candidates|website=historyofvaccines.org|accessdate=17 April 2017}}</ref>  || [[wikipedia:Africa|Africa]]
 +
|-
 +
| 2013 || Update || The [[wikipedia:Malaria Vaccine Technology Roadmap|Malaria Vaccine Technology Roadmap]] (launched in 2006) is updated in November. The update represents a blueprint for second generation malaria vaccine development, including a new Vision, two new Strategic Goals and 13 priority activities.<ref name="Immunization, Vaccines and Biologicals"/>||
 +
|-
 +
| 2014 || Vaccine development (trial) || Initial phase III result at 18 months of [[wikipedia:RTS,S|RTS,S]] trial introduction shows the vaccine efficacy of 46% in children and 27% among young infants against the clinical [[wikipedia:malaria|malaria]].<ref>{{cite web|title=Malaria Vaccine Development: Recent Advances alongside the Barriers|url=https://www.omicsonline.org/open-access/malaria-vaccine-development-recent-advances-alongside-the-barriers-2155-9597-1000300.php?aid=84407|website=omicsonline.org|accessdate=18 April 2017}}</ref> ||
 +
|-
 +
| 2015 || Policy || The [[wikipedia:Committee for Medicinal Products for Human Use|Committee for Medicinal Products for Human Use]] (CHMP) of the [[wikipedia:European Medicines Agency|European Medicines Agency]] (EMA) announces having adopted a positive scientific opinion for [[wikipedia:GlaxoSmithKline|GSK]]’s malaria candidate vaccine [[wikipedia:RTS,S|RTS,S]] (Mosquirix TM), in children aged 6 weeks to 17 months.<ref name="Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )">{{cite web|title=Fact  s heet:  T he RTS,S malaria vaccine candidate (Mosquirix TM )|url=http://www.malariavaccine.org/files/MVI-GSK-RTSSfactsheetFINAL-web.pdf|accessdate=17 April 2017}}</ref><ref name="Questions and answers on RTS,S/ASO1 malaria vaccine"/> ||
 +
|-
 +
| 2016 || Medical development || Biotechnology corporation [[wikipedia:Sanaria|Sanaria]] reports experimental malaria vaccine tested in varying doses providing 55 percent protection for one year to a few volunteers. The vaccine, made by the company, contains thousands of live malaria parasites weakened by [[wikipedia:radiation|radiation]]; the parasites would create an immune response but do not persist in the body for long.<ref>{{cite web|title=A Malaria Vaccine Has Some Success in Testing|url=https://www.nytimes.com/2016/05/10/health/a-malaria-vaccine-has-some-success-in-testing.html?_r=0|website=nytimes.com|accessdate=16 June 2017}}</ref> || United States
 +
|-
 +
| 2016 || Policy || Following the opinion of the [[wikipedia:Committee for Medicinal Products for Human Use|CHMP]], The [[wikipedia:World Health Organization|World Health Organization]] recommends that the pilot implementations use the 4-dose schedule of the RTS,S/AS01 vaccine in 3–5 distinct epidemiological settings in sub-Saharan Africa, at subnational level, covering moderate-to-high transmission settings, with three doses administered to children between 5 and 9 months of age, followed by a fourth dose 15–18 months later.<ref name="Mosquirix™"/><ref name="Questions and answers on RTS,S/ASO1 malaria vaccine"/><ref name="Questions and answers on RTS,S/ASO1 malaria vaccine">{{cite web|title=Questions and answers on RTS,S/ASO1 malaria vaccine|url=http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/|website=who.int|accessdate=17 April 2017}}</ref>  
 +
|-
 +
| 2017 || Report || The World Health Organization Regional Office for Africa (WHO/AFRO) announces on April 24, that Ghana, Kenya, and Malawi will partner with WHO in the Malaria Vaccine Implementation Programme (MVIP) that will make the [[wikipedia:RTS,S|RTS,S]]  vaccine available in selected areas of the three countries.<ref>{{cite web|title=RTS,S|url=http://www.malariavaccine.org/malaria-and-vaccines/first-generation-vaccine/rtss|website=malariavaccine.org|accessdate=25 April 2017}}</ref> || [[wikipedia:Ghana|Ghana]], [[wikipedia:Kenya|Kenya]], [[wikipedia:Malawi|Malawi]]
 +
|-
 +
| 2017 || Medical development || Research team at [[wikipedia:University of Tübingen|University of Tübingen]] in collaboration with biotech company [[wikipedia:Sanaria|Sanaria]] demonstrate 100% effectiveness in clinical trial of new malaria vaccine (Sanaria PfSPZ-CVac), when assessed at 10 weeks after last dose of the vaccine.<ref>{{cite web|title=New malaria vaccine effective in clinical trial|url=https://www.sciencedaily.com/releases/2017/02/170215131606.htm|website=sciencedaily.com|accessdate=16 June 2017}}</ref> || [[wikipedia:Germany|Germany]]
 
|-
 
|-
−
| 2016 || || "17 November 2016, WHO announced that the RTS,S vaccine would be rolled out in pilot projects in 3 countries in sub-Saharan Africa. The pilot programme, coordinated by WHO, will assess the extent to which the vaccine’s protective effect shown in advanced clinical trials (referred to below as “Phase 3 trials”) can be replicated in real-life settings. Specifically, the programme will evaluate the feasibility of delivering the required 4 doses of the vaccine; the impact of the vaccine on lives saved; and the safety of the vaccine in the context of routine use. "<ref name="Questions and answers on RTS,S/ASO1 malaria vaccine">{{cite web|title=Questions and answers on RTS,S/ASO1 malaria vaccine|url=http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/|website=who.int|accessdate=17 April 2017}}</ref>
 
 
|}
 
|}
 +
 +
== Visual data ==
 +
 +
=== Google Trends ===
 +
 +
The comparative chart below shows {{w|Google Trends}} data for Malaria vaccine (Vaccine) and HIV vaccine development (Topic), from January 2004 to March 2020, when the screenshot was taken. Interest is also ranked by country and displayed on world map.<ref>{{cite web |title=Malaria vaccine and HIV vaccine development |url=https://trends.google.com/trends/explore?date=all&q=%2Fm%2F02q78jt,%2Fm%2F012vyq |website=Google Trends |access-date=30 March 2021}}</ref>
 +
 +
[[File:Malaria vaccine and HIV vaccine development gt.png|thumb|center|600px]]
 +
 +
=== Google Ngram Viewer ===
 +
 +
The comparative chart below shows {{w|Google Ngram Viewer}} data for malaria vaccine, influenza vaccine, hiv vaccine, yellow fever vaccine and dengue vaccine, from 1900 to 2019.<ref>{{cite web |title=malaria vaccine, influenza vaccine, hiv vaccine, yellow fever vaccine and dengue vaccine |url=https://books.google.com/ngrams/graph?content=malaria+vaccine%2Cinfluenza+vaccine%2Chiv+vaccine%2Cyellow+fever+vaccine%2Cdengue+vaccine&year_start=1900&year_end=2019&case_insensitive=on&corpus=26&smoothing=3&direct_url=t4%3B%2Cmalaria%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Bmalaria%20vaccine%3B%2Cc0%3B%3BMalaria%20Vaccine%3B%2Cc0%3B%3BMalaria%20vaccine%3B%2Cc0%3B%3BMALARIA%20VACCINE%3B%2Cc0%3B.t4%3B%2Cinfluenza%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Binfluenza%20vaccine%3B%2Cc0%3B%3BInfluenza%20Vaccine%3B%2Cc0%3B%3BInfluenza%20vaccine%3B%2Cc0%3B%3BINFLUENZA%20VACCINE%3B%2Cc0%3B.t4%3B%2Chiv%20vaccine%3B%2Cc0%3B%2Cs0%3B%3BHIV%20vaccine%3B%2Cc0%3B%3BHIV%20Vaccine%3B%2Cc0%3B%3BHIV%20VACCINE%3B%2Cc0%3B.t4%3B%2Cyellow%20fever%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Byellow%20fever%20vaccine%3B%2Cc0%3B%3BYellow%20fever%20vaccine%3B%2Cc0%3B%3BYellow%20Fever%20Vaccine%3B%2Cc0%3B%3BYELLOW%20FEVER%20VACCINE%3B%2Cc0%3B%3BYellow%20Fever%20vaccine%3B%2Cc0%3B.t4%3B%2Cdengue%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Bdengue%20vaccine%3B%2Cc0%3B%3BDengue%20vaccine%3B%2Cc0%3B%3BDengue%20Vaccine%3B%2Cc0#t4%3B%2Cmalaria%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Bmalaria%20vaccine%3B%2Cc0%3B%3BMalaria%20Vaccine%3B%2Cc0%3B%3BMalaria%20vaccine%3B%2Cc0%3B%3BMALARIA%20VACCINE%3B%2Cc0%3B.t4%3B%2Cinfluenza%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Binfluenza%20vaccine%3B%2Cc0%3B%3BInfluenza%20Vaccine%3B%2Cc0%3B%3BInfluenza%20vaccine%3B%2Cc0%3B%3BINFLUENZA%20VACCINE%3B%2Cc0%3B.t4%3B%2Chiv%20vaccine%3B%2Cc0%3B%2Cs0%3B%3BHIV%20vaccine%3B%2Cc0%3B%3BHIV%20Vaccine%3B%2Cc0%3B%3BHIV%20VACCINE%3B%2Cc0%3B.t4%3B%2Cyellow%20fever%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Byellow%20fever%20vaccine%3B%2Cc0%3B%3BYellow%20fever%20vaccine%3B%2Cc0%3B%3BYellow%20Fever%20Vaccine%3B%2Cc0%3B%3BYELLOW%20FEVER%20VACCINE%3B%2Cc0%3B%3BYellow%20Fever%20vaccine%3B%2Cc0%3B.t4%3B%2Cdengue%20vaccine%3B%2Cc0%3B%2Cs0%3B%3Bdengue%20vaccine%3B%2Cc0%3B%3BDengue%20vaccine%3B%2Cc0%3B%3BDengue%20Vaccine%3B%2Cc0 |website=books.google.com |access-date=30 March 2021 |language=en}}</ref>
 +
 +
[[File:Malaria vaccine, influenza vaccine, hiv vaccine, yellow fever vaccine and dengue vaccine ngram.png|thumb|center|700px]]
 +
 +
=== Wikipedia Views ===
 +
 +
The chart below shows pageviews of the English Wikipedia article {{w|Malaria vaccine}}, on desktop from December 2007, and on mobile-web, desktop-spider, mobile-web-spider and mobile app, from July 2015; to February 2021.<ref>{{cite web |title=Malaria vaccine |url=https://wikipediaviews.org/displayviewsformultiplemonths.php?page=Malaria+vaccine&allmonths=allmonths&language=en&drilldown=all |website=wikipediaviews.org |access-date=17 March 2021}}</ref>
 +
 +
[[File:Malaria vaccine wv.png|thumb|center|400px]]
 +
 +
==Meta information on the timeline==
 +
 +
===How the timeline was built===
 +
 +
The initial version of the timeline was written by [[User:FIXME|FIXME]].
 +
 +
{{funding info}} is available.
 +
 +
===Feedback and comments===
 +
 +
Feedback for the timeline can be provided at the following places:
 +
 +
* FIXME
 +
 +
===What the timeline is still missing===
 +
 +
* [https://www.frontiersin.org/articles/10.3389/fimmu.2020.00204/full]
 +
 +
===Timeline update strategy===
 +
 +
=== Pingbacks ===
 +
 +
* [https://books.google.com.ar/books?id=vcdUEAAAQBAJ&pg=PA518&lpg=PA518&dq=timelines.issarice&source=bl&ots=QaZM_D_nxk&sig=ACfU3U2plxF7RA4Hylip_sePrDCy40F23Q&hl=en&sa=X&ved=2ahUKEwjx67Ct1--CAxXER7gEHVKkAUk4ChDoAXoECAIQAw#v=onepage&q=timelines.issarice&f=false ''FAQ on Vaccines and Immunization Practices'', by Vipin Vashishtha and Ajay Kalra] Reference N°6 at page 518
  
 
==See also==
 
==See also==
  
−
== References ==
+
* [[Timeline of malaria]]
 +
* [[Timeline of mosquito net distribution]]
 +
* [[Speculative timeline of future malaria events]]
 +
 
 +
==External links==
 +
 
 +
==References==
 +
 
 +
{{Reflist|30em}}

Latest revision as of 20:26, 1 December 2023

This is a timeline of malaria vaccine, attempting to describe its development. Efforts to develop effective vaccines span for more than six decades.[1]

Big picture

Year/period Key development
1940s-1984 Malaria immunization studies are conducted with aims at developing vaccines.[1]
1984 onward RTS,S, the first malaria vaccine candidate is developed.[2]
1995 onward RTS,S malaria vaccine candidate trials start to be conducted, mostly in Africa.[2]
Present time No effective malaria vaccine exists as of yet.[3]

Timeline

Year/period Type of event Event Location
1942 Immunology development Studies of inactivated sporozoite immunization show apparently beneficial effect of combining induction of cellular and humoral immune responses against malaria of domestic fowl.[1]
1950s Immunology development Research finds that immunization of chickens with a mix of asexual and sexual stages of plasmodium gallinaceum blocks parasite infectivity.[4]
1967 Immunology development Research on avian malaria shows that killed sporozoites as well as sporozoites inactivated with ultraviolet light can produce a partial immunity after injection into birds.[5][6] During the 1960s, the path to malaria vaccine development consolidates with immunization studies of mice with irradiated sporozoites, and posterior analyses of the mechanisms of immunity in this model.[1]
1970 Immunology development Research reveals immune cross protection against malaria in rodent systems.[7]
1983 Publication The first publications for cloning malaria antigens appear.[6]
1984 Program launch The Walter Reed Army Institute of Research (WRAIR) and British pharmaceutical company GlaxoSmithKline (GSK) initiate collaboration to produce a malaria vaccine using GSK’s recombinant escherichia coli expression systems.[2][8]
1985 Immunology development Researchers find that immunization with processed fragments of called Merozoite surface protein-1 MSP-1 (one of the most studied of all malaria proteins) induce protective immune responses.[9]
1986-1987 Immunology development Team lead by Colombian Professor Manuel Elkin Patarroyo inoculates hundreds of aotus monkeys with experimental synthetic proteins designed to imitate bite of malaria proteins. By 1987 Patarroyo reports in Nature Magazine that three particular synthetic proteins protect a significant proportion of monkeys. However, a carrier molecule used to present the peptides to the monkeys’ immune systems appears to damage the animals’ livers.[10] Colombia
1987 Vaccine development Researchers working at GlaxoSmithKline’s (GSK) laboratories, develop malaria vaccine candidate RTS,S (Mosquirix TM).[2] It is the first vaccine created by combining the malaria CS protein and hepatitis B surface antigen.[2] United Kingdom
1993 Vaccine development Study on multi-stage, multi-component malaria vaccine cocktail featuring pre-erythrocytic, blood, and sexual stage antigens gives favourable results, however, further clinical development of this approach would not be reported.[11]
1995 Vaccine development (trial) First RTS,S vaccine clinical tests in humans are conducted in adults in the United States.[2] United States
1997 Vaccine development (trial) RTS,S vaccine Key proof-of-concept (PoC) study shows 100% protection in 6 of 7 volunteers in challenge trial.[2]
1998 Vaccine development (trial) First RTS,S vaccine trials in Africa are conducted in Gambia.[2] Gambia
1999 Program launch The PATH Malaria Vaccine Initiative (MVI) is established, with aims at accelerating the development of malaria vaccines and catalyzing timely access in endemic countries. [12][13] The program launches with a $50 million grant from the Bill & Melinda Gates Foundation.[14]
2001 Organization The GSK/MVI partnership (GlaxoSmithKline and PATH Malaria Vaccine Initiative (MVI)) initiates, with grants from the Bill & Melinda Gates Foundation to PATH, with aims at developing RTS,S vaccine for infants and young children living in malaria-endemic regions in Sub-Saharan Africa."[2]
2003 Vaccine development (trial) RTS,S/AS02A malaria vaccine candidate phase IIb clinical trial is conducted in children from 1 to 4 years of age in Mozambique. The vaccine shows to be safe, immunogenic and efficacious, reducing plasmodium falciparum clinical malaria cases by 30% and episodes of severe disease by up to 58%. In addition, protection would appear to last for a 18 month follow‐up period.[15] Mozambique
2006 Program launch The Malaria Vaccine Technology Roadmap launches.[16][17]
2007 Publication Phase II results in African children and infants are published in The Lancet and The New England Journal of Medicine.[2]
2009-2014 Vaccine development (trial) RTS,S vaccine phase III study is launched in Kisumu, Kenya, in July, under the auspices of the Kenya Medical Research Institute (KEMRI)/CDC Research and Public Health Collaboration.[2][18] The trial would end in 2014, involving 15,459 infants and young children at 11 sites in seven African countries, being the largest malaria vaccine trial in Africa to date.[12][19] Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania
2011 Vaccine development (trial) RTS,S vaccine Phase III trials results, released in October, show that in children aged 5-17 months, vaccination with RTS,S reduce the risk of clinical malaria and severe malaria by 56% and 47%, respectively. However, further results released show the vaccine less effective in infants aged 6-12 weeks at first vaccination.[20] Africa
2013 Update The Malaria Vaccine Technology Roadmap (launched in 2006) is updated in November. The update represents a blueprint for second generation malaria vaccine development, including a new Vision, two new Strategic Goals and 13 priority activities.[16]
2014 Vaccine development (trial) Initial phase III result at 18 months of RTS,S trial introduction shows the vaccine efficacy of 46% in children and 27% among young infants against the clinical malaria.[21]
2015 Policy The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announces having adopted a positive scientific opinion for GSK’s malaria candidate vaccine RTS,S (Mosquirix TM), in children aged 6 weeks to 17 months.[2][22]
2016 Medical development Biotechnology corporation Sanaria reports experimental malaria vaccine tested in varying doses providing 55 percent protection for one year to a few volunteers. The vaccine, made by the company, contains thousands of live malaria parasites weakened by radiation; the parasites would create an immune response but do not persist in the body for long.[23] United States
2016 Policy Following the opinion of the CHMP, The World Health Organization recommends that the pilot implementations use the 4-dose schedule of the RTS,S/AS01 vaccine in 3–5 distinct epidemiological settings in sub-Saharan Africa, at subnational level, covering moderate-to-high transmission settings, with three doses administered to children between 5 and 9 months of age, followed by a fourth dose 15–18 months later.[12][22][22]
2017 Report The World Health Organization Regional Office for Africa (WHO/AFRO) announces on April 24, that Ghana, Kenya, and Malawi will partner with WHO in the Malaria Vaccine Implementation Programme (MVIP) that will make the RTS,S vaccine available in selected areas of the three countries.[24] Ghana, Kenya, Malawi
2017 Medical development Research team at University of Tübingen in collaboration with biotech company Sanaria demonstrate 100% effectiveness in clinical trial of new malaria vaccine (Sanaria PfSPZ-CVac), when assessed at 10 weeks after last dose of the vaccine.[25] Germany

Visual data

Google Trends

The comparative chart below shows Google Trends data for Malaria vaccine (Vaccine) and HIV vaccine development (Topic), from January 2004 to March 2020, when the screenshot was taken. Interest is also ranked by country and displayed on world map.[26]

Malaria vaccine and HIV vaccine development gt.png

Google Ngram Viewer

The comparative chart below shows Google Ngram Viewer data for malaria vaccine, influenza vaccine, hiv vaccine, yellow fever vaccine and dengue vaccine, from 1900 to 2019.[27]

Malaria vaccine, influenza vaccine, hiv vaccine, yellow fever vaccine and dengue vaccine ngram.png

Wikipedia Views

The chart below shows pageviews of the English Wikipedia article Malaria vaccine, on desktop from December 2007, and on mobile-web, desktop-spider, mobile-web-spider and mobile app, from July 2015; to February 2021.[28]

Malaria vaccine wv.png

Meta information on the timeline

How the timeline was built

The initial version of the timeline was written by FIXME.

Funding information for this timeline is available.

Feedback and comments

Feedback for the timeline can be provided at the following places:

  • FIXME

What the timeline is still missing

Timeline update strategy

Pingbacks

See also

External links

References

  1. ↑ 1.0 1.1 1.2 1.3 "Vaccines against malaria". royalsocietypublishing.org. Retrieved 18 April 2017. 
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 "Fact s heet: T he RTS,S malaria vaccine candidate (Mosquirix TM )" (PDF). Retrieved 17 April 2017. 
  3. ↑ "Current Obstacles to Development THE SCIENCE". nap.edu. Retrieved 24 April 2017. 
  4. ↑ "Transmission blocking malaria vaccines: Assays and candidates in clinical development". doi:10.1016/j.vaccine.2015.08.073. Retrieved 25 April 2017. 
  5. ↑ "Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei". nature.com. Retrieved 18 April 2017. 
  6. ↑ 6.0 6.1 "Malaria Vaccine Design: Immunological Considerations". sciencedirect.com. Retrieved 18 April 2017. 
  7. ↑ Peters, Wallace. Antimalarial Drugs I: Biological Background, Experimental Methods, and Drug Resistance. Retrieved 19 April 2017. 
  8. ↑ Ripley Ballou, W.; Cahill, Conor P. "Two Decades of Commitment to Malaria Vaccine Development: Glaxosmithkline Biologicals". Retrieved 19 April 2017. 
  9. ↑ "Malaria vaccines 1985–2005: a full circle?" (PDF). columbia.edu. Retrieved 22 April 2017. 
  10. ↑ "One Colombian's Quest For A Malaria Vaccine". the-scientist.com. Retrieved 22 April 2017. 
  11. ↑ "Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate—Tackling the Cocktail Challenge". plos.org. doi:10.1371/journal.pone.0131456. Retrieved 25 April 2017. 
  12. ↑ 12.0 12.1 12.2 "Fact sheet: R TS,S malaria vaccine candidate (Mosquirix™)" (PDF). malariavaccine.org. Retrieved 17 April 2017. 
  13. ↑ "Malaria Vaccine Initiative". inyvax.eu. Retrieved 18 April 2017. 
  14. ↑ "PATH Malaria Vaccine Initiative (MVI): Accelerating Malaria Vaccine Development". devex.com. Retrieved 25 April 2017. 
  15. ↑ "Towards an effective malaria vaccine". PMC 2066178Freely accessible. doi:10.1136/adc.2005.092551. Retrieved 25 April 2017. 
  16. ↑ 16.0 16.1 "Immunization, Vaccines and Biologicals". who.int. Retrieved 17 April 2017. 
  17. ↑ "Malaria vaccine technology roadmap". doi:10.1016/S0140-6736(13)62238-2. Retrieved 18 April 2017. 
  18. ↑ "Malaria Vaccine". cdc.gov. Retrieved 17 April 2017. 
  19. ↑ "Advances and challenges in malaria vaccine development". PMC 2994342Freely accessible. doi:10.1172/JCI44423. Retrieved 17 April 2017. 
  20. ↑ "Malaria and Malaria Vaccine Candidates". historyofvaccines.org. Retrieved 17 April 2017. 
  21. ↑ "Malaria Vaccine Development: Recent Advances alongside the Barriers". omicsonline.org. Retrieved 18 April 2017. 
  22. ↑ 22.0 22.1 22.2 "Questions and answers on RTS,S/ASO1 malaria vaccine". who.int. Retrieved 17 April 2017. 
  23. ↑ "A Malaria Vaccine Has Some Success in Testing". nytimes.com. Retrieved 16 June 2017. 
  24. ↑ "RTS,S". malariavaccine.org. Retrieved 25 April 2017. 
  25. ↑ "New malaria vaccine effective in clinical trial". sciencedaily.com. Retrieved 16 June 2017. 
  26. ↑ "Malaria vaccine and HIV vaccine development". Google Trends. Retrieved 30 March 2021. 
  27. ↑ "malaria vaccine, influenza vaccine, hiv vaccine, yellow fever vaccine and dengue vaccine". books.google.com. Retrieved 30 March 2021. 
  28. ↑ "Malaria vaccine". wikipediaviews.org. Retrieved 17 March 2021. 
Retrieved from "http://timelines.issarice.com/index.php?title=Timeline_of_malaria_vaccine&oldid=77433"